A Qualitative Systematic Review of Facilitators of and Barriers to Community Pharmacists–Led Anticoagulation Management Service

Oluwaseun Egunsola, PhD1, Joyce W. Li, BSc1, Liza Mastikhina, MSc1, Oluwasefunmi Akeju, MPH1, Laura E. Dowsett, MSc1, and Fiona Clement, PhD1

Abstract

Objective: To identify the facilitators of and barriers to the implementation of Community Pharmacists–Led Anticoagulation Management Services (CPAMS). Data Sources: MEDLINE, EMBASE, CINAHL, Cochrane Database of Systematic Reviews, and Cochrane CENTRAL Register of Controlled Trials were searched from inception until August 20, 2021. Study Selection and Data Extraction: All abstracts proceeded to full-text review, which was completed by 2 reviewers. Data extraction was completed by a single reviewer and verified. Analysis was completed using best-fit framework synthesis. Data Synthesis: A total of 17 articles reporting on CPAMS from 6 jurisdictions were included: 2 Canadian provincial programs (Nova Scotia, Alberta), a national program (New Zealand), and 3 cities in the United Kingdom (Whittington and Brighton and Hove) and Australia (Sydney). Facilitators of CPAMS included convenience for patients, accessibility for patients, professional satisfaction for pharmacists, increased efficiency in anticoagulation management, improved outcomes, enhanced collaboration, and scalability. Barriers included perceived poor quality of care by patients, resistance by general practitioners, organizational limits, capping of the number of eligible patients, and cost. Relevance to Patient Care and Clinical Practice: The barriers and facilitators identified in this review will inform health policy makers on the implementation and improvement of CPAMS for patients and health care practitioners. Conclusion and Relevance: CPAMS has been implemented in 6 jurisdictions across 4 countries, with reported benefits and challenges. The programs were structurally similar in most jurisdictions, with minor variations in implementation. New anticoagulation management programs should consider adapting existing frameworks to local needs.

Keywords

pharmacy, anticoagulation, warfarin, community

Background

Warfarin has been available and used for the prevention and treatment of thromboembolic events for more than 70 years.1 It has been shown to reduce the risk of stroke in patients with atrial fibrillation by 60%.1 To better manage warfarin therapy, some jurisdictions have established specialized anticoagulation clinics.1,2 These anticoagulation management services (AMSs) are provided by health care professionals such as doctors, nurses, and pharmacists, independently or collaboratively.

Anticoagulation services were traditionally provided by physicians in collaboration with onsite or off-site laboratories.3 However, patient-centered models, such as self-testing and self-management, are emerging alternatives that allow those on warfarin to be more involved with their own care. In the self-testing model, the patients perform international normalized ratio (INR) testing by themselves with a point-of-care device and only contact health professionals for interpretation and dose adjustment.4 The self-management model requires patients to monitor their INR values directly, interpret the results, and adjust their warfarin doses using a dosing algorithm.5 Other jurisdictions utilize multidisciplinary approaches to anticoagulation management, with differing levels of responsibility for the members of the health care team.2 Examples

1University of Calgary, Calgary, Alberta, Canada

Corresponding Author:
Fiona Clement, The Department Community Health Sciences, Teaching Research and Wellness Building, 3280 Hospital Drive NW, Calgary Alberta T2N 4N1, Canada. Email: fclement@ucalgary.ca
of multidisciplinary AMS models include pharmacists-led,6,7 pharmacists-assisted,8,9 and nurse-led10 care models. Pharmacists-led anticoagulation services can be provided at the local pharmacies by community pharmacists or in-hospital by clinical or any licensed pharmacists.11,12

Because community pharmacists are the most accessible of all health care providers,13 their involvement in anticoagulation management clinics could significantly increase patients’ access to AMSs.14 Community Pharmacists--Led Anticoagulation Management Services (CPAMS) entail the provision of INR point-of-care testing by community pharmacists and the adjustment of warfarin dose in line with an approved decision-support system.15

Despite its potential for improving anticoagulation management, CPAMS has not been widely adopted. Therefore, the purpose of this systematic review is to identify the facilitators of and the barriers to the implementation of CPAMS across different jurisdictions.

Methods

Search Strategy

A systematic review of the literature was completed. Literature search was conducted in accordance with the Preferred Reporting Items for Systematic reviews and Meta-analyses literature search extension guideline.16 A protocol was not registered. MEDLINE, EMBASE, CINAHL, Cochrane Database of Systematic Reviews, and Cochrane CENTRAL Register of Controlled Trials were searched from inception until August 20, 2021. The search strategy was developed by a research librarian, and peer-review of electronic search strategies was completed by another research librarian.17 The full search strategy is reported in the appendix. The database search was supplemented by a gray literature search guided by the Canadian Agency for Drugs and Technologies in Health’s (CADTH) “Grey Matters” document18 and Google search.

Literature Selection

Calibration with a second reviewer was completed prior to abstract screening and full-text review until >70% agreement was reached. Abstracts identified through database searching were screened in duplicate; all abstracts included by either reviewer proceeded to full-text review. Full-text publications were screened in duplicate. Although the intervention of a third reviewer was planned for any discrepancy, this was not necessary because all discrepancies were resolved by discussion between the 2 reviewers until a consensus was reached. This typically relied on the ability of each reviewer to justify the inclusion or exclusion of the studies. Publications were excluded if they did not meet the inclusion criteria or if the study was not available in English or French. Inclusion criteria were studies or reports on CPAMS program implementation, qualitative evaluation of CPAMS, and program overview. A variety of study designs was expected; therefore, no risk-of-bias assessment was planned.

Data Extraction and Synthesis

A best-fit framework synthesis methodology was used as described by Carroll et al.19 This involved the development of an a priori framework, which provided a structure to the coding and analysis. The framework was developed and translated into nodes and subnodes in NVivo qualitative data analysis software; QSR International Pty Ltd, Version 12. Each subnode represented facilitators of and barriers to CPAMS identified during full-text screening. To ensure consistency between the 2 reviewers, pilot coding was conducted and areas of disagreement discussed. Participant quotations and author synthesis were coded.

Data on study characteristics were extracted onto an Excel sheet by a primary reviewer while another reviewer verified. Disagreements were resolved by discussion. Extracted data included author name, country of study, year of study, type of publication, number of participants, and participant’s demographic characteristics.

Broadly, data synthesis involved the following: (1) description of the review question, (2) identification of relevant literature, (3) framework development, (4) coding the relevant evidence, (5) creation of new themes for those data not captured by the a priori framework, (6) development of an updated framework, (7) understanding the relationships between themes, and (8) narratively describing the findings under 2 broad themes—an overview of CPAMS program implementation and facilitators of and barriers to CPAMS.

This study was conducted in accordance with the Enhancing Transparency in Reporting the Synthesis of Qualitative Research statement.20

Results

Characteristics of Included Studies

The search strategy yielded 934 unique citations. After abstract screening, 149 studies proceeded to full-text review (Figure 1). A total of 133 studies were excluded for the following reasons: not relevant (n = 75), not CPAMS (n = 26), duplicate (n = 19), and did not provide an overview of program, implementation or evaluation (n = 12; Figure 1). In all, 17 studies15,21-36 were included in the final narrative synthesis; 9 of the included studies reported on New Zealand’s CPAMS,27-35 3 reported on Nova Scotia’s (Canada) program,15,21,26 2 involved Boots, the UK anticoagulation program,22,25 and 1 each involved the Alberta
Nine of the studies were program descriptions of CPAMS. There were 5 mixed-method articles. These included the following: a survey and interview of pharmacists on their experience of CPAMS; a survey and interview of patients, general practitioners (GPs), practice nurses, and pharmacists; an economic evaluation and cross-sectional survey of patients and health care workers; a prospective controlled study of the effectiveness of CPAMS, an economic evaluation, and a semistructured interview; and a database analysis and survey of experiences of patients attending CPAMS. There was 1 cross-sectional survey of patients in the New Zealand CPAMS program that evaluated their satisfaction with the program, 1 clinical audit of patients to determine anticoagulant control and compliance with CPAMS, and a prospective cohort study comparing effectiveness of CPAMS with GP-led care.

Overview of CPAMS Implementation Across Jurisdictions. Across jurisdictions, patients were eligible to enroll in a CPAMS program after referral from their physicians. These were generally medically stable patients without significant comorbid conditions. The community pharmacists were empowered to prescribe warfarin, monitor INR with a point-of-care device, and adjust warfarin dosing. Whereas the Canadian and New Zealand programs were primarily driven by provincial and national health agencies, respectively, the Brighton and Hove program in the United Kingdom was facilitated by a pharmacy chain in collaboration with independent pharmacies. In most jurisdictions, community pharmacies volunteered to participate; however, in the Alberta program, pharmacists

---

**Figure 1.** PRISMA flowchart of included studies. 
Abbreviation: CPAMS, Community Pharmacists–Led Anticoagulation Management Services.
| Country       | Author                          | Year                  | Type of publication | Study design         | Number of Participants | Participant characteristics | Testing device      |
|--------------|---------------------------------|-----------------------|---------------------|----------------------|------------------------|-----------------------------|---------------------|
| UK           | Ingram et al                   | 2019                  | Journal article     | Mixed method         | Pharmacies: 8          | Age: 22-106 years           | CoaguChek XS Plus    |
|              |                                 | Implementation year: 2009 |                     | Pharmacist: 7        | Patients: 2341         | Percentage female: 44%      |                     |
|              | Coleman et al                   | 2003                  | Journal article     | Report               | Pharmacies: 1          | Age: NR                     |                     |
|              |                                 | Implementation year: 2002 |                     | Pharmacist: 2        | Patients: 18           | Percentage female: NR       |                     |
|              | Royal Pharmaceutical Society    | 2016                  | Electronic report   | Report               | Pharmacies: NR         | Age: NR                     |                     |
|              |                                 | Implementation year: 2016 |                     | Pharmacist: NR       | Patients: 80           | Percentage female: NR       |                     |
| Canada       | Bungard et al                   | 2006                  | Journal article     | Report               | Pharmacies: 7          | Age: NR                     |                     |
|              |                                 | Implementation year: NR |                     | Pharmacist: 14       | Patients:              | Percentage female: NR       |                     |
|              | Woodill and Bodnar              | 2020                  | Journal article     | Report               | Pharmacies: 40         | Age: NR                     | CoaguChek XS Plus    |
|              |                                 | Implementation year: 2018 |                     | Pharmacist: 946      | Patients: 18           | Percentage female: NR       |                     |
|              | Pharmacy Association of Nova Scotia | 2019               | Electronic report   | NA                   | Pharmacies: 40         | Age: NR                     | CoaguChek XS Pro     |
|              |                                 | Implementation year: 2018 |                     | Pharmacist: 106      | Patients: 946          | Percentage female: 56.6%    |                     |
|              | Pharmacist Association of Nova Scotia | 2015           | Web article         | NA                   | Pharmacies: 40         | Age: NR                     | CoaguChek XS Pro     |
|              |                                 | Implementation year: NR |                     | Pharmacist:          | Patients:              | Percentage female: NR       |                     |
| New Zealand  | Community Pharmacy Warfarin Service | 2011           | Report              | NA                   | Pharmacies: 125        | Age: NR                     | CoaguChek XS Plus   |
|              |                                 | Implementation year: 2012-2013 |                     | Pharmacist: NR       | Patients: NR           | Percentage female: NR       |                     |
|              | Harrison et al                  | 2015                  | Journal article     | Prospective cohort   | Pharmacies: NR         | Age: 72 years, median (13-97) | CoaguChek XS Plus device |
|              |                                 | Implementation year: 2010-2011 |                     | Pharmacist: 41       | Patients: 693          | Percentage female: 37.6     |                     |
|              | Shaw et al                      | 2014                  | Journal article     | Mixed methods        | Pharmacies: 15         | Age: NR                     | CoaguChek XS Plus    |
|              |                                 | Implementation year: NA |                     | Pharmacist: NR       | Patients: 693          | Percentage female: 37.6     |                     |
|              | Harper et al                    | 2015                  | Journal article     | Retrospective cohort | Pharmacies: 126        | Age: 67.65 years, mean (19-97) |                     |
|              |                                 | Implementation year: 2013-2014 |                     | Pharmacist: NR       | Patients: 5866         | Percentage female: NR       |                     |
|              | Shaw et al                      | 2016                  | Journal article     | Mixed methods        | Pharmacies: NR         | Age: NR                     | CoaguChek XS Plus    |
|              |                                 | Implementation year: 2010-2011 |                     | Pharmacist: 41       | Patients: 693          | Percentage female: 37.6     |                     |
|              | Beyene et al                    | 2020                  | Journal article     | Cross-sectional      | Pharmacies: 33         | Age: NR                     | NR                  |
|              |                                 | Implementation year: 2019 |                     | Pharmacist: 305      | Patients:              | Percentage female: 43.3     |                     |
|              | Beyene et al                    | 2020                  | Journal article     | Mixed methods        | Pharmacies: 133        | Age: NR                     | NR                  |
|              |                                 | Implementation year: 2018 |                     | Pharmacist: NR       | Patients:              | Percentage female: 44.1     |                     |
|              | National CPAMS Quality Report   | 2016                  | Report (information sheet) | NA                   | Pharmacies: 150+       | Age: 72 years, median (19-97) | CoaguChek XS Plus   |
|              |                                 | Implementation year: NR |                     | Pharmacist: NR       | Patients: 6000+         | Percentage female: 37.6     |                     |
|              | Shaw et al                      | 2011                  | Report              | Report               | Pharmacies: 15         | Age: 72 years, median (19-97) | CoaguChek XS Plus device |
|              |                                 | Implementation year: 2010-2011 |                     | Pharmacist: 41       | Patients: 693          | Percentage female: 37.6     |                     |
| Australia    | McLachlan et al                 | 2005                  | Electronic report   | Report               | Pharmacies: 7          | Age: 71.9 ± 1.6 years (44)  | INRatio             |
|              |                                 | Implementation year: 2004 |                     | Pharmacist: 44       | Patients:              | Percentage female: 25%       |                     |

Abbreviations: NA, not applicable; NR, not reported.
were required to volunteer and encouraged to establish CPAMS at their local community or hospital pharmacies. Furthermore, the Alberta program allowed some flexibility on program implementation, depending on the location of the pharmacies and availability of resources.

Across jurisdictions, training on anticoagulation management was facilitated by an academic institution. The New Zealand and Nova Scotia programs utilized the INR Online decision support system; while the Brighton and Hove program utilized the DAWN system. In all jurisdictions, physicians continued to provide clinical support for difficult and complicated cases through established communication channels. A brief overview of each jurisdiction is provided in the next section and described in Figure 2.

**CPAMS in Nova Scotia, Canada.** In all, 40 of the 75 pharmacies that applied for the CPAMS demonstration project in Nova Scotia were selected to participate. The selection was implemented such that all counties within the province and all pharmacy banners or chains were represented. Each participating location selected a minimum of 2 pharmacists, with a total of 106 pharmacists participating in the program. Participating pharmacies were paid an INR management fee of $50 CAD per month per patient. Patients were referred by their GPs, who were provided with a referral template, which included details of a collaborative management plan. Supplementary Figure 1 (available online) describes the structure of the CPAMS program in Nova Scotia.

**CPAMS in Alberta, Canada.** In Alberta, anticoagulant management services were implemented using a 3-staged approach. The first stage involved the establishment of an AMS within a quaternary care setting; the second involved...
the training of selected pharmacists; and the third involved the implementation of community AMSs. A total of 7 pharmacies and 14 pharmacists were involved in this program. All program sites were required to have a minimum of 1 physician serving as the medical director, and pharmacists were required to commit to undergo the requisite training and hold anticoagulation clinics 3 days per week.

**CPAMS Implementation in New Zealand.** The first pilot CPAMS project at a community pharmacy in New Zealand was implemented in 2009, followed by a larger pilot in late 2010. The participating GPs transferred authorities for specific aspects of anticoagulation management, for specific patients to the pharmacists, using informed consent forms and standing order delegations. Eligibility for referral to the program was dependent on the absence of specific comorbidities. Pharmacies were required to have preexisting good relationships with local GPs. All participating pharmacists were paid per patient to cover the cost of time and consumables and to set up the program.

**CPAMS in Brighton and Hove, UK.** In 2009, a UK pharmacy chain began to operate a community pharmacist-led anticoagulation service in the Brighton and Hove area of England. A total of 17 pharmacies participated in the program. All pharmacists completed a 3-day training course on anticoagulation management at the National Centre for Anticoagulation and also received training on service procedures.

**CPAMS in Whittington, UK.** In 2002, a 9-month pilot community pharmacy-based AMS was implemented at a community pharmacy close to Whittington, UK. Pharmacists received training on the finger-prick technique for blood sampling, use of a portable coagulometer, and use of the computerized anticoagulant advisory system. They also attended a 1-day first-aid course. This was an appointment-based service, which operated 1 afternoon every week and was managed by 2 pharmacists. An audit system was implemented to ensure the accuracy of the coagulometer.

**CPAMS in Sydney, Australia.** In 2004, pharmacists from 8 community pharmacies in the Sydney metropolitan area were invited to participate in a CPAMS program in order to compare clinical outcomes with usual care provided in 5 other pharmacies. Interested pharmacists attended an educational seminar on anticoagulation management and committed to providing the service to patients participating in the study for 12 months. The pharmacists provided consultation at least once per month to check the patients’ INR, provide dietary and lifestyle advice, make dosing recommendations, and monitor adherence to anticoagulant treatment. The dosage recommendations were made in consultation with the patients’ GPs, and no dosing decisions were made without the final approval of the GPs.

**Facilitators of CPAMS Across Jurisdictions (Figure 3)**

**Convenience.** Patient participants reported that CPAMS was more convenient than usual GP care. According to a patient in the Sydney program, “It was quick and easy, no waiting and no booking.”

Much of the time gained was from the point-of-care testing, for which the results were available almost immediately. Several patients reported that it was easy for them to go for their anticoagulation treatment at the same time as they went for their local shopping, and some pharmacies offered flexibility in appointment, which were not available with GPs. One convenience noted by GPs was that they were able to reallocate the extra time and resources to other areas of their practice.

In addition, capillary samples for point-of-care testing were easier to collect than venous samples for laboratory tests. The immediate availability of INR results, immediate dose adjustments, and a reduction in waiting time also contributed to lower stress reported across patients.

“I am pleased to have the results of my reading immediately and that they prick my finger not my arm.”

**Accessibility.** Some patients found pharmacists to be easily accessible. As a result, they were able to confer with them about issues they believed did not necessitate a GP consultation. This resulted in a better understanding of their condition. Some patients found the hospitals to be too busy but were able to easily get appointments with their pharmacists under the CPAMS program. The ease of securing an appointment with the pharmacist was highly appreciated by the patients.

**Figure 3.** Facilitators of and barriers to CPAMS. Abbreviations: CPAMS, Community Pharmacists–Led Anticoagulation Management Services; GP, general practitioner.
Increased Efficiency for the Patient and System. Several patients found CPAMS to be more streamlined than GP care, given that all aspects of anticoagulation management could be carried out in the pharmacy. CPAMS allowed some of the GPs to spend less time on warfarin management, particularly on reviewing results and adjusting doses. The GPs reported being pleased that the pharmacists were handling these aspects of their patient care. It was also reported to be easier for the pharmacists to modify warfarin doses at the time of consultation without having to rely on the patient’s laboratory bloodwork results. The provision of information in real time also meant that the GPs did not have to track down patients to relay test results and dosing information.

According to one patient, “The doctor’s system is in four stages . . . blood taken, to lab, lab faxes to doctor’s reception, to duty nurse, then doctor approves. Too many rooms for mistakes.”

Some participants highlighted the ability of the CPAMS model to improve efficiency in the health care system. According to them, CPAMS has the potential to reduce the burden on GPs and laboratories. GP s in New Zealand were able to reallocate their time and resources to other aspects of their practice, which resulted in overall time and cost savings. The cost of delivering CPAMS in New Zealand was 30% lower than the cost of the standard care model. The program was also believed to have kept patients out of the emergency room because of enhanced access to care. CPAMS freed up capacity in the hematology departments of some hospitals in the United Kingdom, allowing increased focus on patients with more complex needs.

Improved Clinical Outcomes. CPAMS in Nova Scotia resulted in increased adherence to testing and medications, with almost 80% of INR tests completed on or before their due date. Patients generally found the dosing schedule provided by community pharmacists to be easier than usual care. In addition, health outcomes, such as time within therapeutic range, were reportedly better with CPAMS in Nova Scotia than usual care. Approximately 71% of patients in the CPAMS program had INR in therapeutic range compared with historical values of 50% to 60%. Participants felt that CPAMS increased the safety of anticoagulation management because INR results and dose adjustments were immediately available.

Scalability. CPAMS was implemented in several jurisdictions as pilot programs, involving limited numbers of patients and pharmacies. Some of the interviewed pharmacists believed that it would be easy to implement the program on a larger scale as soon as the constraints of lack of funding and trained pharmacies were addressed.

Professional Satisfaction for Pharmacists. Pharmacists across several jurisdictions identified professional satisfaction as one of the reasons for participating in the program. Some pharmacists in New Zealand had thought that their clinical skills were underutilized prior to CPAMS and found the program to be a natural extension of the counseling and dispensing they had been providing to patients receiving anticoagulants. For some pharmacists in the United Kingdom, it was an opportunity for clinical development and practice toward being an independent prescriber.

In Nova Scotia, some pharmacists reported improved job satisfaction, finding it rewarding to use their clinical skills to work more closely with patients.

“CPAMS is the most rewarding project I have been involved in as a pharmacist thus far in my career. I truly enjoyed the collaboration, the patient experiences, and the [opportunity] to practice at a higher level. I always see the benefits to our patients and the cost savings to our health care system. It’s a win for all.”

For several pharmacists participating in the Nova Scotia and New Zealand CPAMS programs, their comfort and confidence in managing anticoagulation increased substantially over the course of the program. This increase in clinical confidence among New Zealand pharmacists led to the implementation of additional clinical services, such as medicines use review and smoking cessation support.

Enhanced Collaboration. Some patients noted that CPAMS fostered collaboration between them, the GPs, and pharmacists.

“There was a three-way communication between me, the pharmacist and the doctor”

Although several pharmacists already had good working relationships with GPs, CPAMS strengthened many of these existing relationships. GPs and patients also developed a better understanding of the value that pharmacists provide to patients. The interaction between patients and pharmacists increased patients’ involvement with their treatment, which contributed to improved adherence. Pharmacists also noted that patients’ trust and confidence in them increased over time and they were more likely to share relevant health information with them. As a result, the pharmacists were able to identify other health needs and address them.

Barriers to CPAMS Across Jurisdictions (Figure 3)

Perceived Quality of Care. Some patients, particularly at the initial stage of CPAMS, had doubts about the quality of
care they would receive at the pharmacies. For example, one person in New Zealand reported feeling like the computer was making the treatment decisions for them rather than the pharmacist.

“The pharmacist does not manage my warfarin treatment—a computer programme does. I am not confident of the programme’s decisions.”

A number of patients doubted the ability of pharmacists to manage their warfarin, with some believing that warfarin dose management may be well above their level of competence. Such considerations led to initial hesitancy in the uptake of CPAMS, especially among patients who had experienced previous adverse effects with warfarin.

**Resistance From GPs.** Some CPAMS locations in New Zealand were unable to enroll their target number of patients because GPs withdrew or withheld their support. The pharmacists noted that some GPs would have found the program more acceptable if they had been approached via a GP organization rather than by the pharmacists directly. The GPs’ reluctance sometimes stemmed from their concern about who was ultimately responsible for the patients if things went wrong. Others were protective of their patients and did not see the need for pharmacists to do anticoagulation management, whereas some believed that the pharmacists were incapable of providing the service. There were also concerns about the warfarin doses recommended by the decision support system, with a number of GPs noting that the algorithm did not account for patient factors, such as noncompliance.

**Funding.** In New Zealand, a number of pharmacists believed that the funding model for CPAMS, which was based on the number of patients enrolled at each pharmacy per month rather than the number of consults that patients required, was suboptimal. They noted that this costing model did not factor in the needs of complicated patients who may require additional consultations. Similarly, pharmacists in the Nova Scotia program noted that the monthly fee allocated for each patient was sufficient for the standard stable patient who was tested every 28 days but not for unstable patients with more frequent testing needs.

Patients who had been receiving free GP and laboratory services had varying opinions about paying for CPAMS. Whereas some reported that they would happily pay for the service, others said that they would rather return to GP-led care if payment is required for participating in CPAMS after the pilot was over.

“I would go back to lab if I did have to pay a fee for pharmacy.”

Other patients said that they would struggle to pay for CPAMS but felt that the service was worth paying for. In Nova Scotia, for example, the majority of patients could not afford to pay the full costs of service, which was 54 CAD per month, whereas some patients in the Sydney program suggested a fee range from $10 to $20 per visit. In the Sydney program, the pharmacists believed that the level of remuneration did not reflect the time and effort required by them and the GPs.

**Capping.** The CPAMS program in New Zealand capped the number of patients enrolled per pharmacy. This resulted in some patients, who wanted the service but could not access it, paying out of pocket for the service, whereas some others were placed on a waitlist. Additionally, there was a cap on the number of pharmacies providing CPAMS. Details regarding the extent of the capping were not provided in any of the New Zealand studies.

**Organizational Limits.** The amount of time spent on consultations at the beginning of CPAMS in New Zealand was initially high because all the patients were on a weekly INR testing regimen. Pharmacies had to juggle the staffing demands of CPAMS with meeting other service demands. For some pharmacies, the uncertainty around the amount of time to allocate to CPAMS at the expense of other services was a hindrance to uptake.

“I think that you need to have a decent amount of staff in the pharmacy to be able to do it. I mean, you are taking up a pharmacist’s variable amount of time, sometimes it can be quick and easy, but other times sorting things out will take a bit longer. Not every pharmacy can do it.” (p. 260)

Furthermore, some pharmacies did not have the layout or staff that permits the implementation of CPAMS. One of the main challenges observed in the Nova Scotia program was the nonintegration of patients’ INR test results with the electronic health systems in the province. There were also challenges in communicating patients’ warfarin treatment to their GPs.

**Discussion**

This systematic review describes CPAMS implementation in 6 jurisdictions across 4 different countries. Although barriers, such as funding, capacity issues, and resistance by some GPs, were identified, CPAMS was shown to be convenient, accessible, efficient, and scalable. However, very few jurisdictions have fully adopted the program. The utilization of a decision support system for CPAMS also offered unique advantages, such as the calculation of recommended warfarin doses, appointment setting, calculation of the time in therapeutic range for each patient, and the mean time in
therapeutic range for each pharmacy. It also tracks compliance with appointments, test frequency, and adverse events. Patient information can be easily retrieved, thereby ensuring efficient patient audit. A limitation of this systematic review is the reliance on a limited number of studies; thus, findings were mostly seen through the lens of a few researchers and a few jurisdictions. Second, we did not conduct quality assessment of the studies included in the review because the study types were varied and consisted mainly of reports.

Relevance to Patient Care and Clinical Practice

CPAMS have been shown to improve safety outcomes in patients receiving warfarin therapy. However, the implementation of this model of AMS has not been widely adopted. This is the first systematic review evaluating the factors affecting CPAMS implementation across multiple jurisdictions. The barriers, facilitators, and implementation considerations identified in this review will inform health policy makers on how to implement and improve CPAMS for patients and health care practitioners.

Conclusion and Relevance

CPAMS has been implemented in 6 jurisdictions across 4 countries, with reported benefits and challenges. Some of the benefits of CPAMS included convenience, increased collaboration between doctors and pharmacists, ability to scale, improved clinical outcomes, and increased efficiency. However, barriers to CPAMS were also identified, including lack of funding, resistance from GPs, organizational limits, and perceived poor quality of care by the patients. The programs were structurally similar in most jurisdictions, with minor variations in implementation. New anticoagulation management programs should consider adapting existing frameworks to local needs.

Appendix

Search Strategy

CINAHL CPAM Search. December 31, 2020

1. ( (MH "Anticoagulants") OR (MH "Warfarin")) OR TI ( (adoisine or aldoucumar or anticoagula* or anticoagula* or antirhombin* or antirhombin* or befarin or carfin or couvrit or coumadin* or coumaphine or coumaphine or dagonal or farin or jantovon or kumatox or maforan or marevan or orfarin or panwarfarin or panwarfin or prothromadin or simarc-2 or sofarin or tecicumur or thrombin inhibitor* or tintorane or uniwarfin or waran or warfarin* or warfant or warnerin) ) OR AB ( (adoisine or aldoucumar or anticoagula* or anticoagula* or antirhombin* or antirhombin* or befarin or carfin or couvrit or coumadin* or coumaphine or coumaphine or dagonal or farin or jantovon or kumatox or maforan or marevan or orfarin or panwarfarin or panwarfin or prothromadin or simarc-2 or sofarin or tecicumur or thrombin inhibitor* or tintorane or uniwarfin or waran or warfarin* or warfant or warnerin) ) OR AB ( (adoisine or aldoucumar or anticoagula* or anticoagula* or antirhombin* or antirhombin* or befarin or carfin or couvrit or coumadin* or coumaphine or coumaphine or dagonal or farin or jantovon or kumatox or maforan or marevan or orfarin or panwarfarin or panwarfin or prothromadin or simarc-2 or sofarin or tecicumur or thrombin inhibitor* or tintorane or uniwarfin or waran or warfarin* or warfant or warnerin) )

MEDLINE

1. anticoagulants/ or warfarin/
2. (adoisine or aldoucumar or anticoagula* or anticoagula* or antirhombin* or antirhombin* or befarin or carfin or couvrit or coumadin* or coumaphine or coumaphine or dagonal or farin or jantovon or kumatox or maforan or marevan or orfarin or panwarfarin or panwarfin or prothromadin or simarc-2 or sofarin or tecicumur or thrombin inhibitor* or tintorane or uniwarfin or waran or warfarin* or warfant or warnerin).tw,kf.
3. 1 or 2
4. Community Pharmacy Services/
5. Pharmacies/
6. Pharmacists/
7. Pharmaceutical Services/
8. (chemist or chemists or druggist* or pharmaceutical service* or pharmacist* or pharmacy or pharmacies).tw,kf.
9. 5 or 6 or 7 or 8
10. (community or communities or local or retail).tw,kf.
11. 9 and 10
12. (apothecaries or apothecary or chemist* shop* or drugstore* or drug store*).tw,kf.
13. 4 or 11 or 12
EMBASE
1. warfarin/
2. (adoisine or aldocumar or anticoagula* or anticoagula* or antrombin or athrombin* or befar or carfin or circuvit or coumadin* or coumafene or coumaphene or dagonal or farin or jantoven or kumatox or maforan or marevan or orfarin or panwarfarin or panwarfin or prothromadin or simarc-2 or sofarin or tedicum or thrombin inhibitor* or tintorane or uniwarfin or waran or warfar or warfarin* or warfant or warnerin).tw,kw.
3. 1 or 2 or 3
4. "pharmacy (shop)"/
5. community pharmacist/
6. ((community or communities or local or retail) adj5 (chemist or chemists or druggist* or pharmacist* or pharmacy or pharmacies)).tw,kw.
7. (apothecaries or apothecary or chemist* shop or drug store* or drugstore*).tw,kw.
8. 5 or 6 or 7 or 8
9. 4 and 9
10. animals/ not human/
11. 10 not 11

Cochrane Database of Systematic Reviews and DARE
1. anticoagulants/ or warfarin/
2. (adoisine or aldocumar or anticoagula* or anticoagula* or antrombin or athrombin* or befar or carfin or circuvit or coumadin* or coumafene or coumaphene or dagonal or farin or jantoven or kumatox or maforan or marevan or orfarin or panwarfarin or panwarfin or prothromadin or simarc-2 or sofarin or tedicum or thrombin inhibitor* or tintorane or uniwarfin or waran or warfar or warfarin* or warfant or warnerin).tw.
3. 1 or 2
4. Community Pharmacy Services/
5. Pharmacies/
6. Pharmacists/
7. Pharmaceutical Services/
8. (chemist or chemists or druggist* or pharmaceutical service* or pharmacist* or pharmacy or pharmacies).tw.
9. 5 or 6 or 7 or 8
10. (community or communities or local or retail).tw.
11. 9 and 10
12. (apothecaries or apothecary or chemist* shop or drugstore* or drug store*).tw.
13. 4 or 11 or 12
14. 3 and 13
15. animals/ not humans/
16. 14 not 15

Authors’ Note
FC, OE, JWL, and LED conceptualized the study. OE, LED, LM, JWL, and OA acquired the data. OE, LED, and JWL drafted the article. FC, LM, and OA revised the article for critically important intellectual content. All authors approved the final version of the article.

Declaration of Conflicting Interests
The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Research was supported by the Health Technology Assessment Office, Province of BC. The views expressed herein do not necessarily represent those of the Government of British Columbia

ORCID iD
Oluwaseun Egunsola https://orcid.org/0000-0002-0500-9501

Supplemental material
Supplemental material for this article is available online.

References
1. Harper P. The clinical importance of extending the Community Pharmacy Anticoagulation Management Service. Accessed August 10, 2021. https://www.psnz.org.nz/Folder?Action=View%20File&Folder_id=86&File=ClinicalImportanceOfExtendingCPAMS.pdf
2. Bungard T, Grant CM, Ackman ML, Tsuyuki RT. Anticoagulation clinics in North America: operational insights. Can J Hosp Pharm. 2008;61(4). doi:10.4212/cjhp.v61i4.62

3. Jones C, Lacombe G. Enhancing patient care via a pharmacist-managed rural anticoagulation clinic. Healthc Q. 2009;13(spec no.):69-74. doi:10.12927/hecq.2009.21101

4. Kulfis J, Money AG, Perry M, Barnett J, Young T. Technology-assisted self-testing and management of oral anticoagulation therapy: a qualitative patient-focused study. Scand J Caring Sci. 2017;31:603-617. doi:10.1111/scs.12374

5. Jowett S, Bryan S, Murray E, et al. Patient self-management of anticoagulation therapy: a trial-based cost-effectiveness analysis. Br J Haematol. 2006;134:632-639. doi:10.1111/j.1365-2411.2006.06243.x

6. Barrios AC, Ventura HO, Milani RV. The comprehensive management of anticoagulation: Ochsner Coumadin Clinic. Ochsner J. 2002;4:37-40.

7. Gupta V, Kogut SJ, Thompson S. Evaluation of differences in percentage of international normalized ratios in range between pharmacist-led and physician-led anticoagulation management services. J Pharm Pract. 2015;28:249-255. doi:10.1177/1076029614531638

8. Kong M, Ng H, Lee P, Chan Y, Tan D, Lee L. Implementation and impact of a hybrid pharmacist-assisted anticoagulation clinic model on the quality of anticoagulation therapy. Clin Appl Thromb Hemost. 2012;18:334-337. doi:10.1177/1076029611424738

9. Ko EK, Pearson GJ. Implementation and evaluation of a pharmacist-assisted warfarin dosing program. Can J Hosp Pharm. 2018;50(4). doi:10.4212/cjhp.v50i4.2067

10. Rudd KM, Dier JG. Comparison of two different models of anticoagulation management services with usual medical care. Pharmacotherapy. 2010;30:330-338. doi:10.1592/phco.30.4.330

11. Sylvester KW, Ting C, Lewin A, et al. Expanding anticoagulation management services to include direct oral anticoagulants. J Thromb Thrombolysis. 2018;45:274-280. doi:10.1007/s11239-017-1602-1

12. Bungard TJ, Archer SL, Hamilton P, Ritchie B, Tymchak W, Tsuyuki RT. Bringing the benefits of anticoagulation management services to the community: Alberta program may serve as a model of care. Can Pharm J. 2006;139:58-64. doi:10.1177/171516350613900207

13. Ibrahim MIM, Wertheimer A. Social and Administrative Aspects of Pharmacy in Low- and Middle-Income Countries: Present Challenges and Future Solutions. Academic Press; 2017. Accessed May 10, 2021. https://www.sciencedirect.com/book/9780128112281/social-and-administrative-aspects-of-pharmacy-in-low-and-middle-income-countries

14. Macgregor SH, Hamley JG, Dunbar JA, Dodd TR, Cromarty JA. Evaluation of a primary care anticoagulant clinic managed by a pharmacist. BMJ. 1996;312:560. doi:10.1136/bmj.312.7030.560

15. Pharmacy Association of Nova Scotia. Community pharmacist-led anticoagulation management service Nova Scotia demonstration project. Accessed January 31, 2021. https://pans.ns.ca/system/files/files/page/cpams_-_information_for_pharmacy.pdf

16. Rethlefsen ML, Kirtley S, Waffenschmidt S, et al. PRISMA-S: an extension to the PRISMA statement for reporting literature searches in systematic reviews. Syst Rev. 2021;10:39. doi:10.1186/s13643-020-01542-z

17. McGowan J, Sampson M, Salzwedel D, Cogo E, Foerster V, Lefebvre C. PRESS peer review of electronic search strategies: 2015 guideline statement. J Clin Epidemiol. 2016;75:40-46. doi:10.1016/j.jclinepi.2016.01.021

18. Canadian Agency for Drugs and Technologies in Health (CADTH). Grey matters: a practical tool for searching health-related grey literature. Accessed June 24, 2021. https://www.cadth.ca/resources/finding-evidence

19. Carroll C, Booth A, Leaviss J, Rick J. “Best fit” framework synthesis: refining the method. BMC Med Res Methodol. 2013;13:37. doi:10.1186/1471-2288-13-37

20. Tong A, Flemming K, McInnes E, Oliver S, Craig J. Enhancing Transparency in Reporting the Synthesis of Qualitative Research: ENTREQ. BMC Med Res Methodol. 2012;12:181. doi:10.1186/1471-2288-12-181

21. Woodill L, Bodnar A. A novel model of care in anticoagulation management. Healthc Manage Forum. 2020;33:247-252. doi:10.1177/0840470420969444

22. Ingram SJ, Kirkdale CL, Williams S, et al. Moving anticoagulation initiation and monitoring services into the community: evaluation of the Brighton and Hove community pharmacy service. BMC Health Serv Res. 2018;18:91. doi:10.1186/s12913-018-2901-8

23. Bungard TJ, Archer SL, Hamilton P, Ritchie B, Tymchak W, Tsuyuki RT. Bringing the benefits of anticoagulation management services to the community. Can Pharm J. 2006;139:58-64. doi:10.1177/171516350613900207

24. Coleman B, Patterson D, Long M, Farrell J. Setting quality standards for a community pharmacist-led anticoagulant clinic. Pharm J. 2003;270:308-311.

25. Royal Pharmaceutical Society. Frontline pharmacists: making a difference for people with long term conditions. Published November 24, 2016. Accessed August 26, 2021. https://www.evidence.nhs.uk/document?id=2241630&returnUrl=search?q=pharmacist&q=pharmacist

26. Pharmacy Association of Nova Scotia. Final Evaluation of the Community Pharmacist-led Anticoagulation Management Service (CPAMS) Canada Project. Accessed March 10, 2021. https://pans.ns.ca/sites/default/files/final_evaluation_report_final_-_pans_cpams_eval_2019.09.25.pdf

27. Shaw J, Harrison J, Harrison J. Community Pharmacist-Led Anticoagulation Management Service Final Report. School of Pharmacy, The University of Auckland; 2011. Accessed August 10, 2021. https://www.moh.govt.nz/notebook/nbbooks.nsf/0/4C2CF8F6912A75A4CC257C9F0060D1E41/$file/Pharmacy%20AMS%20demonstration%20final%20evaluation%20report.pdf

28. Harrison J, Shaw JP, Harrison JE. Anticoagulation management by community pharmacists in New Zealand: an evaluation of a collaborative model in primary care. Int J Pharm Pract. 2015;23:173-181. doi:10.1111/ijpp.12148

29. Shaw J, Harrison J, Harrison J. A community pharmacist-led anticoagulation management service: attitudes towards a new collaborative model of care in New Zealand. Int J Pharm Pract. 2014;22:397-406. doi:10.1111/ijpp.12097
30. Harper P, McMichael I, Griffiths D, Harper J, Hill C. The community pharmacy-based anticoagulation management service achieves a consistently high standard of anticoagulant care. *N Z Med J*. 2015;128:31-41.

31. Community Pharmacy Warfarin Service. Community Pharmacy Anti-Coagulation Management (CPAM) service: information for general practice. Accessed March 10, 2021. http://www.coaguchek.co.nz/content/dam/internet/dia/coaguchek/coaguchek_co_nz/coaguchek_hcp/pdf/CPAMS%20Information%20for%20General%20Practice.pdf

32. Shaw J, Harrison J, Harrison J. Evaluation of the Community Pharmacist-led Anticoagulation Management Service (CPAMS) pilot program in New Zealand. In: *Economic Evaluation of Pharmacy Services*. Elsevier; 2017: 159-181.

33. Beyene K, Chan AHY, Bandreddi NST, et al. Patient satisfaction with community pharmacist-led anticoagulation management services and its relationship with patient characteristics in New Zealand. *Int J Clin Pharm*. 2021;43:154-164. doi:10.1007/s11096-020-01124-y

34. Beyene K, Chan AHY, Barton E, et al. Pharmacists views on participating in New Zealand’s community pharmacy anticoagulation management service: a mixed-methods study. *Int J Clin Pharm*. 2021;43:251-262. doi:10.1007/s11096-020-01148-4

35. Community Pharmacy Anti-Coagulation Management Service (CPAMS): information for primary and community care. Accessed March 10, 2021. https://www.inronline.ca/wp-content/uploads/2017/05/CPAMS-Primary-Community-Care-Information.pdf

36. McLachlan A, Spindler M, Fois R, Krass I, Chen T, Bajorek B. *A Community Pharmacy Based Anticoagulant Management Service*. The Pharmacy Guild of Australia; 2005. Accessed August 10, 2021. https://6cpa.com.au/wp-content/uploads/A-community-pharmacy-based-anticoagulant-management-service-final-report.pdf

37. Jackson SL, Peterson GM, Vial JH, Jupe DML. Improving the outcomes of anticoagulation: an evaluation of home follow-up of warfarin initiation. *J Intern Med*. 2004;256:137-144. doi:10.1111/j.1365-2796.2004.01352.x

38. Stafford L, Peterson GM, Bereznicki L.R, et al. Clinical outcomes of a collaborative, home-based postdischarge warfarin management service. *Ann Pharmacother*. 2011;45:325-334. doi:10.1345/aph.1P617